CLEAR 1002-043 (Follow-up)
A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant
- Medicine
- bepedoic acid
- Population
- ASCVD
- Phase
- III
- Starting year
- 2016
- More information
- Clinicaltrials.gov